PGEN

Precigen ($PGEN) Executives Continue Buying Spree After Kirk's $20M Investment, CFO Adds More Shares

09/30/2025 20:15

A series of insider purchases by Precigen ($PGEN) executives is drawing investor attention. In late September, CFO Harry Thomasian Jr. made consecutive purchases totaling $40,000 worth of shares over two days, while the COO and CCO also bought shares worth $6,800 and $21,480 respectively. This continues the insider buying pattern that began with director Randal J. Kirk's massive $20 million purchase of 23.52 million shares in August 2024. Precigen is a clinical-stage biotechnology company headquartered in Germantown, Maryland, specializing in innovative gene and cell therapies. Founded in 1998, the company focuses on developing treatments for immuno-oncology, autoimmune disorders, and infectious diseases, utilizing proprietary platforms including AdenoVerse adenovectors and UltraCAR-T chimeric antigen receptor T cell therapies. Current clinical pipeline includes PRGN-3005 (ovarian cancer), PRGN-3006 (acute myeloid leukemia), and AG019 (type 1 diabetes). The timing of executive purchases appears highly strategic. Kirk's massive purchase occurred in August 2024 when shares traded at $0.85, while recent CFO purchases happened at $3.4-3.6 levels in September. Despite the stock's 300%+ gain over the year, continued executive buying suggests management sees additional upside potential from current levels. Kirk's $20 million investment particularly stands out as more than a confidence signal—it represents strong conviction in the company's future. As a veteran biotech investor through Third Security LLC with investments across multiple biotech companies, his substantial commitment signals high evaluation of Precigen's technological potential and commercialization prospects. Financially, the company shows typical clinical-stage biotech characteristics with annual revenue of $4.34 million against net losses of $124.5 million. However, recent success in securing $125 million in non-dilutive financing for PAPZIMEOS commercialization and partnership with EVERSANA for U.S. commercialization creates a monetization foundation. Current cash reserves of approximately $59.75 million provide near-term operational runway. Analyst sentiment remains positive with average price targets of $6-8, suggesting 60-100% upside from recent trading levels around $3.8. Projections anticipate 2026 revenue surging to $108.91 million with EPS turning positive at $0.06, contingent on successful PAPZIMEOS commercialization. Investors should carefully monitor clinical trial results and commercialization progress. Successful PAPZIMEOS market adoption could validate analyst projections, but clinical failures or regulatory delays could pressure current high valuations with P/S ratios at 234x reflecting substantial future growth expectations. Nevertheless, continuous insider buying provides positive signals, particularly the CFO's post-rally purchases demonstrating confidence in upcoming performance improvements. With beta at 1.82 indicating high volatility, a long-term perspective focused on clinical results and commercialization milestones appears more appropriate than short-term trading strategies.